{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:33:54Z","timestamp":1774953234301,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.oret.2020.07.003","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T21:26:55Z","timestamp":1594243615000},"page":"141-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"5","author":[{"given":"Nathan C.","family":"Steinle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiming","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namrata","family":"Saroj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2020.07.003_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/2040622312446007","article-title":"Aflibercept in wet age-related macular degeneration: a perspective review","volume":"3","author":"Ohr","year":"2012","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.oret.2020.07.003_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/archophthalmol.2010.318","article-title":"Prevalence of age-related macular degeneration in the US population","volume":"129","author":"Klein","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2020.07.003_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0002-9440(10)64525-7","article-title":"Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization","volume":"157","author":"Spilsbury","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.oret.2020.07.003_bib4","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1517\/14712598.2015.1057565","article-title":"Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration","volume":"15","author":"Yazdi","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.oret.2020.07.003_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0974-9233.173133","article-title":"Management of neovascular age-related macular degeneration: a review on landmark randomized controlled trials","volume":"23","author":"Agarwal","year":"2016","journal-title":"Middle East Afr J Ophthalmol"},{"key":"10.1016\/j.oret.2020.07.003_bib6","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.07.003_bib7","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ophtha.2006.10.045","article-title":"Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration","volume":"114","author":"Boyer","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.07.003_bib8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2007.08.012","article-title":"Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results","volume":"144","author":"Kaiser","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2020.07.003_bib9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","article-title":"Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration","volume":"120","author":"Ying","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.07.003_bib10","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.07.003_bib11","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ajo.2015.07.034","article-title":"Baseline predictors of 12-month treatment response to ranibizumab in patients with wet age-related macular degeneration","volume":"160","author":"Regillo","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2020.07.003_bib12","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1167\/iovs.08-3225","article-title":"Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials","volume":"50","author":"Suner","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2020.07.003_bib13","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ophtha.2013.11.022","article-title":"Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials","volume":"121","author":"Thach","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.07.003_bib14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.oret.2019.03.008","article-title":"Detection of nonexudative choroidal neovascularization and progression to exudative choroidal neovascularization using OCT angiography","volume":"3","author":"Bailey","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2020.07.003_bib15","doi-asserted-by":"crossref","first-page":"e911","DOI":"10.1111\/aos.13751","article-title":"Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies","volume":"96","author":"Lanzetta","year":"2018","journal-title":"Acta Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653020302815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653020302815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:29:19Z","timestamp":1762853359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653020302815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S2468653020302815"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2020.07.003","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2020.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}